ClariVest Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

ClariVest Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$2.8M	Hold	43,911	–	–	0.29%	82
2024 Q2	$2.8M	Sell	43,911 -6,199	-12%	-$402K	0.29%	82
2024 Q1	$3.46M	Sell	50,110 -71	-0.1%	-$4.29K	0.36%	56
2023 Q4	$2.77M	Sell	50,181 -1,157	-2%	-$63.7K	0.15%	103
2023 Q3	$2.98M	Buy	51,338 +13,792	+37%	+$796K	0.16%	92
2023 Q2	$2.02M	Buy	+37,546	New	+$1.66M	0.1%	130
2022 Q2	–	Sell	-18,643	Closed	-$524K	–	687
2022 Q1	$524K	Sell	18,643 -2,953	-14%	-$110K	0.02%	379
2021 Q4	$995K	Buy	21,596 +21,553	+50,123%	+$926K	0.03%	319
2021 Q3	$1K	Buy	+43	New	+$1.34K	﹤0.01%	662
2015 Q2	–	Sell	-40,550	Closed	-$2.54M	–	605
2015 Q1	$2.54M	Buy	40,550 +2,026	+5%	+$123K	0.08%	158
2014 Q4	$2.17M	Sell	38,524 -6,477	-14%	-$286K	0.08%	150
2014 Q3	$1.27M	Sell	45,001 -35	-0.1%	-$1.05K	0.05%	217
2014 Q2	$1.55M	Sell	45,036 -11,578	-20%	-$363K	0.06%	200
2014 Q1	$1.77M	Buy	+56,614	New	+$1.5M	0.07%	177

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

ClariVest Asset Management's ANIP Position: Q3 2024 in Review

ClariVest Asset Management held its ANI Pharmaceuticals (ANIP) position steady in Q3 2024 at 43,911 shares worth $2.8M. The position accounts for 0.29% of the portfolio, ranked #82.

ClariVest Asset Management first reported a position in ANIP in Q1 2014 and has held it in 14 quarters since. The position peaked at $3.46M in Q1 2024. 208 funds tracked by Wall St. Rank hold ANIP as of Q3 2024.

ClariVest Asset Management held 43,911 shares of ANI Pharmaceuticals worth $2.8M as of Q3 2024.
ClariVest Asset Management left its ANI Pharmaceuticals share count unchanged in Q3 2024.
ANI Pharmaceuticals made up 0.29% of ClariVest Asset Management's portfolio in Q3 2024, its #82 holding.
ClariVest Asset Management first reported a position in ANI Pharmaceuticals in Q1 2014 and has held it in 14 quarters since.
ClariVest Asset Management's ANI Pharmaceuticals position peaked at $3.46M in Q1 2024.
208 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.